Fosun secured rights to AriBio’s oral Phase 3 Alzheimer’s therapy AR-1001 in a structured option deal that totals potential consideration of up to $4.7 billion, according to reporting. Fosun will gain global exclusive rights excluding South Korea, the Middle East and South America, building on existing regional permissions in mainland China, Hong Kong and Macao plus select ASEAN countries. In parallel, BMS and Hengrui signed a collaboration spanning 13 early-stage programs across oncology, hematology and immunology with payments potentially exceeding $15 billion. The structure includes global strategic collaboration and license agreements, with Hengrui overseeing early development for acceleration. Taken together, the deals show continued appetite for late-phase Alzheimer’s exposure and for large-scale, multi-program risk-sharing in oncology discovery and early clinical proof-of-concept.